Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDXCNASDAQ:PHATNASDAQ:SPRONASDAQ:STOK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDXCChromaDex$6.16$2.31▼$9.18$611.50M2.21807,851 shs554,788 shsPHATPhathom Pharmaceuticals$10.03+11.0%$4.47$2.21▼$19.71$700.23M0.081.48 million shs3.58 million shsSPROSpero Therapeutics$2.89+3.2%$1.13$0.51▼$3.06$161.58M1.311.14 million shs2.12 million shsSTOKStoke Therapeutics$11.82+2.8%$9.18$5.35▼$17.58$627.87M1.09699,920 shs500,444 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDXCChromaDex0.00%0.00%0.00%+0.32%+159.57%PHATPhathom Pharmaceuticals+10.95%+113.86%+203.02%+127.44%-7.73%SPROSpero Therapeutics+3.21%+12.89%+318.84%+269.38%+102.10%STOKStoke Therapeutics+2.78%+8.64%+32.36%+37.44%-31.24%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCDXCChromaDex2.6104 of 5 stars3.50.00.04.00.60.01.9PHATPhathom Pharmaceuticals4.0835 of 5 stars4.52.00.00.03.15.00.6SPROSpero Therapeutics3.883 of 5 stars3.32.00.04.73.40.00.6STOKStoke Therapeutics3.9033 of 5 stars3.60.00.04.83.91.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDXCChromaDex 3.00Buy$9.03∞ UpsidePHATPhathom Pharmaceuticals 3.00Buy$17.5074.48% UpsideSPROSpero Therapeutics 2.50Moderate Buy$5.0073.01% UpsideSTOKStoke Therapeutics 3.29Buy$23.2096.28% UpsideCurrent Analyst Ratings BreakdownLatest SPRO, PHAT, CDXC, and STOK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/9/2025PHATPhathom PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $17.006/9/2025PHATPhathom PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.006/6/2025PHATPhathom PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.005/14/2025STOKStoke TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/14/2025STOKStoke TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$47.00 ➝ $35.005/2/2025PHATPhathom PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$10.00 ➝ $5.005/2/2025PHATPhathom PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $12.005/2/2025PHATPhathom PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$28.00 ➝ $20.004/21/2025PHATPhathom PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.004/17/2025PHATPhathom PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$12.00 ➝ $10.004/9/2025PHATPhathom PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDXCChromaDex$99.60M0.00N/AN/A$0.38 per share0.00PHATPhathom Pharmaceuticals$81.86M8.55N/AN/A($1.27) per share-7.90SPROSpero Therapeutics$28.30M5.71$1.78 per share1.62$2.02 per share1.43STOKStoke Therapeutics$190.91M3.38N/AN/A$3.57 per share3.31Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDXCChromaDex-$4.94M$0.10787.290.00N/A1.62%4.85%2.70%N/APHATPhathom Pharmaceuticals-$201.59M-$5.24N/AN/AN/A-1,292.14%N/A-79.57%8/6/2025 (Estimated)SPROSpero Therapeutics$22.81M-$1.2841.29N/AN/A3.30%4.03%2.21%8/4/2025 (Estimated)STOKStoke Therapeutics-$104.70M$0.79N/AN/AN/A-629.90%-54.45%-40.77%8/5/2025 (Estimated)Latest SPRO, PHAT, CDXC, and STOK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025SPROSpero Therapeutics-$0.55-$0.25+$0.30-$0.25$11.00 million$5.87 million3/27/2025Q4 2024SPROSpero Therapeutics-$0.35-$0.38-$0.03-$0.38$12.40 million$15.04 million3/24/2025Q4 2024STOKStoke Therapeutics-$0.56-$0.18+$0.38-$0.18$4.20 million$22.61 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCDXCChromaDexN/AN/AN/AN/AN/APHATPhathom PharmaceuticalsN/AN/AN/AN/AN/ASPROSpero Therapeutics$0.062.08%N/AN/A N/ASTOKStoke TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDXCChromaDexN/A2.952.35PHATPhathom PharmaceuticalsN/A5.735.68SPROSpero TherapeuticsN/A2.682.68STOKStoke TherapeuticsN/A5.095.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDXCChromaDex15.41%PHATPhathom Pharmaceuticals99.01%SPROSpero Therapeutics25.60%STOKStoke TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipCDXCChromaDex9.64%PHATPhathom Pharmaceuticals23.00%SPROSpero Therapeutics5.50%STOKStoke Therapeutics9.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDXCChromaDex12077.75 million69.02 millionOptionablePHATPhathom Pharmaceuticals11069.81 million51.90 millionOptionableSPROSpero Therapeutics15055.91 million52.05 millionOptionableSTOKStoke Therapeutics10054.60 million46.98 millionOptionableSPRO, PHAT, CDXC, and STOK HeadlinesRecent News About These CompaniesCantor Fitzgerald Predicts STOK FY2026 EarningsJune 10 at 8:30 AM | marketbeat.comKangaroo Care Awareness Day celebrated at Stoke Mandeville HospitalJune 10 at 7:41 AM | msn.comJong Oranje and Stoke City star is open to transfer: “Of course, I have my ambitions”June 10 at 7:41 AM | sports.yahoo.comStoke City confirm next stage of major badge consultationJune 10 at 7:41 AM | msn.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stock Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK)June 10 at 3:21 AM | marketbeat.comStoke Therapeutics, Inc. (NASDAQ:STOK) Shares Sold by Two Sigma Investments LPJune 9, 2025 | marketbeat.comJane Street Group LLC Sells 318,465 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)June 8, 2025 | marketbeat.comAnalysts Set Stoke Therapeutics, Inc. (NASDAQ:STOK) Target Price at $23.20June 8, 2025 | americanbankingnews.comStoke City Secure Youth International Amid Leeds United InterestJune 7, 2025 | therealefl.co.ukFive hours of 'thundery showers' to rock Stoke-on-Trent todayJune 7, 2025 | msn.comBusiness forum will look at how the Stoke-on-Trent and Staffordshire area sells itself to the worldJune 7, 2025 | expressandstar.comCelebrations as Stoke-on-Trent turns 100 years oldJune 7, 2025 | bbc.comLeeds United dealt transfer blow as Stoke City near 'two-year deal' for England youth internationalJune 7, 2025 | yorkshirepost.co.ukHuddersfield Town confirm departure of 125-appearance man as Stoke City snap up former Hull City targetJune 7, 2025 | yorkshirepost.co.ukLive updates as Lancaster Bomber performing Stoke-on-Trent flypastJune 7, 2025 | stokesentinel.co.ukJon Walters opens up on Sorba Thomas transfer tussle as Stoke City make first moveJune 7, 2025 | msn.comMillennium Management LLC Increases Position in Stoke Therapeutics, Inc. (NASDAQ:STOK)June 7, 2025 | marketbeat.comBarry Ticho Sells 1,745 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) StockJune 5, 2025 | marketbeat.comStoke Therapeutics, Inc. (NASDAQ:STOK) Insider Barry Ticho Sells 6,471 SharesJune 5, 2025 | marketbeat.comStoke Therapeutics, Inc. (NASDAQ:STOK) Insider Barry Ticho Sells 1,745 SharesJune 5, 2025 | insidertrades.comStoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Recommendation of "Buy" from AnalystsJune 5, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsSprouts Stock: Insider Sales, But Strong Bullish SignalsBy Thomas Hughes | May 19, 2025View Sprouts Stock: Insider Sales, But Strong Bullish SignalsSPRO, PHAT, CDXC, and STOK Company DescriptionsChromaDex NASDAQ:CDXCChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.Phathom Pharmaceuticals NASDAQ:PHAT$10.03 +0.99 (+10.95%) As of 06/12/2025 04:00 PM EasternPhathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.Spero Therapeutics NASDAQ:SPRO$2.89 +0.09 (+3.21%) As of 06/12/2025 04:00 PM EasternSpero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.Stoke Therapeutics NASDAQ:STOK$11.82 +0.32 (+2.78%) As of 06/12/2025 04:00 PM EasternStoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ignore the Noise—Samsara Stock Is Still a Strong Buy Oracle’s Cloud Boom Is Just Getting Started Netflix Sets New Highs—Price Targets Keep Climbing IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA Alibaba’s Dip Is a Gift—Here’s the Price That Matters Betting on Disruption: Is Lemonade the Future of Insurance? Starbucks Stock: Culture Fix May Be Key to Long-Term Growth GameStop Turns a Profit, But Core Business Keeps Shrinking Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
